IFNG and gastric cancer: Upon binding to the proline- and glutamine-rich splicing factor SFPQ in both gastric cancer cells and T cells, circMAN1A2 promotes G1/S-phase progression in gastric cancer cells while inhibiting T-cell receptor (TCR) signaling and the secretion of TNF-α and IFN-γ, thereby attenuating antitumor immune responses and driving gastric cancer progression (69).